Evaluating Pain Relief After Dental Implant Surgery Using 0.3% Benzydamine Hydrochloride Spray: A Double-Blind, Randomized Clinical Trial

J Oral Implantol. 2026 Feb 17;52(1):46-52. doi: 10.1563/aaid-joi-D-25-00034.

ABSTRACT

Effective postoperative pain control is essential for patient comfort following dental implant surgery. This double-blind, randomized clinical trial evaluated the efficacy of 0.3% benzydamine hydrochloride (BNZD) spray, an anti-inflammatory and topical analgesic agent, compared with placebo in patients undergoing single posterior implant placement. Thirty healthy adults were randomly allocated to either BNZD (n = 15) or placebo (n = 15). Pain intensity was assessed using a visual analog scale (VAS) at 3, 6, 18, 24, 48, and 72 hours postoperatively. The frequencies of spray use and the number of rescue analgesic tablets taken were also recorded. The VAS scores decreased progressively in both groups with no significant difference in immediate postoperative pain. However, a significant reduction in pain was observed at 18 hours in the BNZD group. Notably, the BNZD group reached a VAS score of 0 by 72 hours, whereas the placebo group continued to report residual pain. A significantly lower frequency of spray application was observed in the BNZD group (P = .03). Although not statistically significant, fewer rescue analgesics were used in the BNZD group. These findings suggest that 0.3% BNZD spray may reduce the frequency of analgesic use and expedite pain resolution following implant surgery. Although overall pain reduction was similar between groups, the earlier achievement of pain-free status with BNZD suggests potential clinical benefit. Further studies with larger cohorts are recommended to confirm its efficacy.

PMID:41702593 | DOI:10.1563/aaid-joi-D-25-00034